A Study of Aleglitazar in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00388518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 6 arm study will assess the efficacy, safety, tolerability and pharmacokinetics of aleglitazar therapy in patients with Type 2 diabetes. Patients will be randomised to one of 6 treatment arms, to receive one of 4 doses of aleglitazar, Actos as an open-label active comparator, or placebo. Aleglitazar will be administered starting from a dose of 0.05mg po daily, and Actos will be administered at a dose of 45mg once daily. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00388518
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 332 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2006 (Type not available)
- Primary completion
- Mar 2008 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- Nov 2, 2016
2006 – 2008
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85006 | — |
| Not listed | Phoenix | Arizona | 85029 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Palm Springs | California | 92262 | — |
| Not listed | San Diego | California | 92161 | — |
| Not listed | Chiefland | Florida | 32626 | — |
| Not listed | Hollywood | Florida | 33023 | — |
| Not listed | West Palm Beach | Florida | 33401 | — |
| Not listed | Augusta | Georgia | 30909 | — |
| Not listed | Idaho Falls | Idaho | 83404 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Baton Rouge | Louisiana | 70809 | — |
| Not listed | Baltimore | Maryland | 21229 | — |
| Not listed | Olive Branch | Mississippi | 38654 | — |
| Not listed | Hamilton | New Jersey | 08610 | — |
| Not listed | New Hyde Park | New York | 11042 | — |
| Not listed | Johnson City | Tennessee | 37604 | — |
| Not listed | Spokane | Washington | 99216 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00388518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2016 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00388518 live on ClinicalTrials.gov.